TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Freedom from procedure-related primary adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Relative Duration With Oxygen Saturation (SpO2) Within Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With SpO2 Less Than 88%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who start planned dialysis initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Disabilities of the Arm, Shoulder, and Hand
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Exercise performance - VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise workload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysgeusia (Phantogeusia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ONH vessels density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: AUC of GFCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biologic blood counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Surgical repair success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in retinal oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in retinal oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epworth scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Adoption and Use of IT Platform
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Engagement of Medicaid Member Participants with Peer Integration Care Services
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Total Cost of Care for Participating Members
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time of complete healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flow mediated vasodilation of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: count values for detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static 2-point Discrimination Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Immunogenicity as assessed by serum IgG antibody levels specific for the F protein antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 2 Year Disease-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: RNA content of circulating particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean NICU length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean maximum glucose infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Data quality
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence of proprioceptive organs in the muller muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of twin to twin transfusion syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Cormack-Lehane Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epiglottis skin distance in centimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyoid bone-skin distance in centimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior commissure-skin distance in centimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of tongue root in centimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indirect Laryngoscopic Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total MADRS Scores From Baseline to Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Discontinuation Emergent Signs and Symptoms Check List (DESS)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Safety as Assessed by the Arizona Sexual Experience Scale (ASEX)
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Events
Endpoint domain: Mortality/survival
Primary endpoint: Elevation of Cardiac Enzyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of benefit of return of research results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cosmetic effects
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Loco-regional relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Progression rate at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive enhancement of working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of Eyes With Monocular Visual Acuity Better Than 20/40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Eyes With Absolute Rotation Less Than or Equal to 10 Degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Eyes With Lens Stability With Blink Within 5 Degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subject Eyes With Acceptable Lens Fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnoea Hypopnoea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vaginal Cuff Closure Times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Accurate Epidural Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in pulsatility index in umbilical and uterine arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of Seraffix System
Endpoint domain: Adverse events/effects
Primary endpoint: Delay in development of clinically definite multiple sclerosis (MS)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients using the system
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Average Total Urine Output at End of Treatment (EOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Number of Stools Per Day at EOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: C-reactive protein, plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral for Kidney Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Skin microvascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: senescence markers in adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adipose tissue quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise induced leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Density Lipoproteins (LDL) cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High Density Lipoproteins (HDL) cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline index of microcirculatory resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: outcomes of treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Non Progression at 4 Months
Endpoint domain: Mortality/survival
Primary endpoint: Patient controlled analgesics (PCA) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h post-dose trough forced expiratory volume in 1 second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with abnormal findings in 12-lead safety Electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of Proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: area stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: thrombus or ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Posttraumatic Stress Disorder severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual TCD screening rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in phenolic acid metabolite excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montgomery-Åsberg Depression Rating Scale (MADRS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate and its variability (RR slope and RMSSD values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal Aspartate Aminotransferase Level Within 7 Postoperative Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximal Alanine Aminotransferase Level Within 7 Postoperative Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of Plasma 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy based on symptomatic urinary tract infection (UTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in plaque volume and composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hemodynamic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified BORG score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate-specific Antigen (PSA) Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of crying and fussing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of responders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean delay to recovery of neuromuscular blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PrEP adherence/persistence by measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of social harms (SHs)
Endpoint domain: Adverse events/effects
Primary endpoint: Self-report of any IPV
Endpoint domain: Adverse events/effects
Primary endpoint: New atelectasis for each segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Atelectasis for each patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ICU delirium duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Residual Neuromuscular Blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Benefit/risk ratio of treatments
Endpoint domain: Resource use
Primary endpoint: Measurement of pancreatic polypeptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in rate of EMS calls
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Transient Lower Esophageal Sphincter Relaxations (TLESRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pulmonary Function Test (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary Function Test (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of Acute Exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: HIV infection detected by 4 months
Endpoint domain: Mortality/survival
Primary endpoint: Magnitude of the reduction in mother-to-child HIV transmission
Endpoint domain: Mortality/survival
Primary endpoint: Magnitude of the increase in non-HIV-related under-2-year mortality
Endpoint domain: Mortality/survival
Primary endpoint: Tumor expression of immune markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolic characteristics on FDG-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of organic bowel diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of questions answered by each patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of days with severe mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol-related attitude
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximal Power Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Survival With a Functioning Graft
Endpoint domain: Mortality/survival
Primary endpoint: Canada activity performance measure (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline MIS at 6th month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline serum albumin at 6th month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Change in Percentage Body Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of perampanel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of perampanel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) of perampanel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility and Acceptability of Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tear Film Evaporation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early diagnosis of oral neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Gastrocnemius Muscle Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Ankle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in Pain Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate relief for global IBS symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subjective Comfort After Contact Lens Insertion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective Dryness After Contact Lens Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Rating of Clarity of Vision After Contact Lens Insertion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neonatal morbidity composite measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Contaminated Cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of microhaemorrhages (RMH) on magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of remote haematomas (RH) on magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes of high sensitivity troponin I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antibody levels for diphtheria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody levels for pertussis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody levels for tetanus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody levels for mumps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody levels for measles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline General Self-Efficacy Scale (GSE) at 2 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline State-Trait Anxiety Inventory Questionnaire (STAI) at 2 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Atopic Dermatitis Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain induced by insertion of the quadhelix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response at Week 12 (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Score on the Hamilton Anxiety Scale (HAM-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ultrasonographic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in CD8 + T-cell specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence and severity of local side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence and severity of systemic side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: Size of change in summation skin flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Pediatric Stroke Outcome Measure at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery and Recurrence Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: King's Outcome Scale for Childhood Head Injury (KOSCHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of cetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the severity of pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ultrasound lumen area at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Minimal lumen diameter at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: injection site skin reactions
Endpoint domain: Adverse events/effects
Primary endpoint: GAD65A titer in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Global assessment of functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of completion of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of grade II-IV GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Speech recognition in quiet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Speech recognition in noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of nonoccupational post-exposure prophylaxis with Eviplera
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of escalating doses of NGRhTNF
Endpoint domain: Adverse events/effects
Primary endpoint: Change in levels of IFN-g [pg/ml]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in levels of calprotectin [pg/ml]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Response Rate (Complete and Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative abundance of PF-04991532 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radioactivity AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgery volume
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Dietary Lapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unauthorized drug use
Endpoint domain: Adverse events/effects
Primary endpoint: SCL-90
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SAS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HBV Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes